Japan Approves Dupixent as First Targeted Treatment for Bullous Pemphigoid

Japan's Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for the treatment of adults with bullous pemphigoid (BP). This marks the first time a targeted therapy has been authorized for this chronic autoimmune skin disease in the Japanese market. The regulatory decision was supported by positive results from pivotal clinical trials demonstrating the drug's efficacy. Data showed that patients treated with Dupixent achieved sustained disease remission at a rate over four times higher than those on placebo through Week 36. Developed through a global collaboration between Sanofi and Regeneron, Dupixent continues to expand its therapeutic indications. This approval is expected to further solidify the drug's position as a primary revenue driver for both pharmaceutical giants.

Sources:globenewswire.comglobenewswire.commarketscreener.comaktiencheck.demanagedhealthcareexecutive.comsimplywall.stmanilatimes.netnationaltoday.comfinanznachrichten.debenzinga.comreuters.comfiercepharma.combusinesswire.com